Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer-Reference-Cited by-同舟云学术

Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer

Published:2016-03 Issue:7 Volume:114 Page:737-743
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Stein Stacey M,James Edward S,Deng Yanhong,Cong Xiangyu,Kortmansky Jeremy S,Li Jia,Staugaard Carol,Indukala Doddamane,Boustani Ann Marie,Patel Vatsal,Cha Charles H,Salem Ronald R,Chang Bryan,Hochster Howard S,Lacy Jill

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc201645.pdf

Reference23 articles.

1. Callery M, Chang K, Fishman E, Talamonti MS, William Traverso L, Linehan DC (2009) Pretreatment assessment of resectable and borderline resectable pancreatic cancer: Expert Consensus Statement. Ann Surg Oncol 16 (7): 1727–1733.

2. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364 (19): 1817–1825.

3. Conroy T, Paillot B, Francois E, Bugat R, Jacob JH, Stein U, Nasca S, Metges JP, Rixe O, Michel P, Magherini E, Hua A, Deplanque G (2005) Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer – a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol 23 (6): 1228–1236.

4. Day F, Link E, Ngan S, Leong T, Moodie K, Lynch C, Michael M, Winton Ed, Hogg A, Hicks RJ, Heriot A (2011) FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy. Br J Cancer 105 (4): 498–504.

5. Faris J, Blaszkowsky L, McDermott S, Guimaraes AR, Szymonifka J, Huynh MA, Ferrone CR, Wargo JA, Allen JN, Dias LE, Kwak EL, Lillemoe KD, Thayer SP, Murphy JE, Zhu AX, Sahani DV, Wo JY, Clark JW, Fernandez-del Castillo C, Ryan DP, Hong TS (2013) FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist 18 (5): 543–548.

Cited by 157 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modeling health outcomes associated with BRCA testing and treatment strategies for patients with metastatic pancreatic cancer;Pancreatology;2024-01

2. Krüppel-like Factor 10 as a Prognostic and Predictive Biomarker of Radiotherapy in Pancreatic Adenocarcinoma;Cancers;2023-10-30

3. Overall survival and treatment modalities in pancreatic adenocarcinoma: a retrospective analysis of a single centre in Western Australia;Journal of Gastrointestinal Oncology;2023-10

4. Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial;BMC Cancer;2023-09-21

5. Developments and challenges in neoadjuvant therapy for locally advanced pancreatic cancer;World Journal of Gastroenterology;2023-09-21